Status:
TERMINATED
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Adult Acute Lymphoblastic Leukemia in Remission
Adult Grade III Lymphomatoid Granulomatosis
Eligibility:
All Genders
18-78 years
Phase:
NA
Brief Summary
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and p...
Detailed Description
PRIMARY OBJECTIVES: I. To determine whether the addition of plerixafor improves the proportion of patients with lymphoma who collect \>= 8 x 10\^6 cluster of differentiation (CD)34+ cells/kg within t...
Eligibility Criteria
Inclusion
- Have biopsy-confirmed non-Hodgkin lymphoma, of any type
- Must be eligible for autologous transplantation according to institutional guidelines
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Karnofsky performance status of 70 to 100
- Negative for human immunodeficiency virus (HIV)
- prior to the start of mobilization, subjects must have:
- Absolute neutrophil count of \>= 1.2 x 10\^9/L
- Platelet count of \>= 100 x 10\^9/L
- Creatinine clearance \>= 30 mL/minute
- All patients must be able to comprehend and sign informed consent
- If childbearing potential must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization and for at least 3 months following last plerixafor dose; female patients will undergo pregnancy test prior to stem cell mobilization therapy
Exclusion
- Have had previous transplants and/or prior mobilization attempts
- Have evidence of progressive non-Hodgkin lymphoma
- Have evidence of bone marrow involvement of lymphoma at time of transplant staging
- Had evidence of active central nervous system (CNS) involvement
- Have had previous radiation of the pelvic area
- Have had prior radioimmunotherapy
- Have received experimental therapy within 2 weeks of enrollment
- Be currently enrolled in another investigational protocol
- Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01408043
Start Date
October 1 2011
End Date
May 1 2016
Last Update
June 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44195